M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.
Davide Rossi,C Lobetti Bodoni,Elisa Genuardi,Luigia Monitillo,Daniela Drandi,Michaela Cerri,Clara Deambrogi,Irene Ricca,Alberto Rocci,Simone Ferrero,Elisa Bernocco,Daniela Capello,L De Paoli,Luciana Bergui,Michela Boi,Paola Omedè,Massimo Massaia,Corrado Tarella,Roberto Passera,Mario Boccadoro,Gianluca Gaidano,Marco Ladetto +21 more
TL;DR: It is demonstrated that TL is a powerful independent predictor of multiple outcomes in CLL, and contributes to refine the prognostic assessment of this disease when utilized in combination with other prognostic markers.
Journal ArticleDOI
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
F. Fiore,Barbara Castella,Barbara Nuschak,Raffaello Bertieri,Sara Mariani,Benedetto Bruno,Francesca Pantaleoni,Myriam Foglietta,Mario Boccadoro,Massimo Massaia +9 more
TL;DR: Large numbers of gammadelta T cells with effector and costimulatory activities are rapidly generated by Zol-treated iDC/mDC, and this strategy is worthy of further investigation to improve adoptive cell therapy and vaccine interventions against tumors and infections.
Journal ArticleDOI
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.
Benedetto Bruno,Marcello Rotta,Francesca Patriarca,Daniele Mattei,Bernardino Allione,Fabrizio Carnevale-Schianca,Roberto Sorasio,Alessandro Rambaldi,Marco Casini,Matteo Parma,P Bavaro,Francesco Onida,Alessandro Busca,Luca Castagna,Edoardo Benedetti,Anna Paola Iori,Luisa Giaccone,Antonio Palumbo,Paolo Corradini,Renato Fanin,David G. Maloney,Rainer Storb,Ileana Baldi,Umberto Ricardi,Mario Boccadoro +24 more
TL;DR: This tandem transplantation approach allows prolonged survival and long-term disease control in patients with reduced tumor burden at the time of allografting and is currently investigating the role of "new drugs" in intensifying pretransplantation cytoreduction and posttransplantation graft-versus-myeloma effects to further improve clinical outcomes.
Journal ArticleDOI
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
Heinz Ludwig,Meral Beksac,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Michele Cavo,Meletios A. Dimopoulos,Johannes Drach,Hermann Einsele,Thierry Facon,Hartmut Goldschmidt,Jean-Luc Harousseau,Urs Hess,Nicolas Ketterer,Martin Kropff,Larisa P. Mendeleeva,Gareth J. Morgan,Antonio Palumbo,Torben Plesner,Jesús F. San Miguel,Ofer Shpilberg,Pia Sondergeld,Pieter Sonneveld,Sonja Zweegman +23 more
TL;DR: This review presents an overview of the most recent data using the novel agents thalidomides, bortezomib, and lenalidomide in the treatment of multiple myeloma and summarizes European treatment practices incorporating these novel agents.
Journal ArticleDOI
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Heinz Ludwig,Pieter Sonneveld,Faith E. Davies,Joan Bladé,Mario Boccadoro,Michele Cavo,Gareth J. Morgan,Javier de la Rubia,Michel Delforge,Meletios A. Dimopoulos,Hermann Einsele,Thierry Facon,Hartmut Goldschmidt,Philippe Moreau,Hareth Nahi,Torben Plesner,Jesús F. San-Miguel,Roman Hájek,Pia Sondergeld,Antonio Palumbo +19 more
TL;DR: In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option, and Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency.